Background-Enoxaparin inhibits smooth muscle cell proliferation in experimental models. Intimal hyperplasia has been found to be the principal cause of restenosis after coronary stent implantation. We sought to determine whether the intramural delivery of enoxaparin before stenting of de novo lesions decreases restenosis. Methods and Results-One hundred patients who were undergoing stenting were randomly assigned to either local administration of enoxaparin during predilation with reduced systemic heparinization or stenting with standard, systemic heparinization. All patients were treated with the same type of stent (NIR). The primary study end point was late luminal loss. The secondary end points were major adverse cardiac events, target lesion revascularization, and angiographic restenosis at 6 months. Angiographic follow-up at 6 months was completed in all except 1 patient. Late luminal loss was reduced to 0.76Ϯ0.42 mm in the local enoxaparin delivery group versus 1.07Ϯ0.49 mm in the systemic heparinization group (PϽ0.001). Restenosis, using a binary definition, occurred in 10% of patients in the enoxaparin group and in 24% of patients in the systemic heparinization group (PϽ0.05). Target lesion revascularization rates occurred in 8% of the enoxaparin group and 22% of the systemic heparinization group (PϽ0.05). There were no deaths and no emergent CABGs were performed. The only subacute stent closure and non-Q-wave infarction occurred in a patient assigned to the systemic heparinization group. Conclusions-This is the first prospective randomized trial in which the local delivery of a drug, enoxaparin, resulted in significant reduction in late luminal loss and restenosis after stent implantation in de novo coronary lesions. 
S
tenting of discrete lesions in large coronary arteries results in lower restenosis rates than conventional coronary angioplasty. [1] [2] [3] Restenosis, however, remains an important and costly therapeutic problem. Because intimal smooth muscle cell proliferation 4 -7 is in large part the culprit, various attempts to inhibit this process have been studied. 8 -13 Reduction in in-stent restenosis was described with the application of ␥-and ␤-irradiation. 14 -16 Several investigators proposed the use of local drug delivery as a strategy for the treatment of restenosis after intervention. [17] [18] [19] [20] [21] [22] [23] Modulation of the stimuli for neointimal hyperplasia with the appropriate pharmacological agents would, in theory, permit vessel wall healing after coronary stent implantation without an exaggerated, obstructive proliferative response. Thus far, local drug delivery of various agents and different methods of administration has failed to affect restenosis rate after stenting. 24, 25 This may be related to the agent studied, the design of the delivery device, and both the methods and timing of drug delivery with respect to stenting. Arterial injury triggers thrombus formation with the release of growth factors known to stimulate neointimal proliferation: platelet-derived growth factor, transforming growth factor-␤, fibroblast growth factor, and others. 26 -28 Such an interaction may contribute to restenosis. Therefore, to modulate the magnitude of thrombin-and thrombus-mediated stimuli for neointimal proliferation, we chose low-molecular-weight heparin (enoxaparin; Aventis), a potent factor Xa and thrombin inhibitor, 29, 30 to be specifically administered during predilation.
Enoxaparin has been shown to inhibit smooth muscle cell proliferation at high tissue concentrations. [31] [32] [33] However, it has not reduced the incidence of angiographic restenosis or clinical events after successful coronary angioplasty when administered systemically. 34 Because the antiproliferative effect of enoxaparin on smooth muscle proliferation appears to be dose dependent, we used a microporous, local drug delivery/angioplasty catheter (Transport catheter; Boston Scientific) simultaneously for predilation and the administration of enoxaparin, followed by stent deployment. To minimize trauma to the wall, we delivered small volumes of highly concentrated drug at low pressures. 35, 36 We postulated that this approach combined with subsequent compression of the treated wall segment by the expanded stent would result in a sufficient local concentration and retention of enoxaparin to prevent subacute stent closure and to decrease intimal hyperplastic response. This strategy, if effective, would reduce late luminal loss and, ultimately, the restenosis rate. Thus, we conducted an initial, multicenter, prospective, randomized study in which we compared stenting after local delivery of enoxaparin with reduced systemic heparinization and traditional stenting using full systemic heparinization. To eliminate any differences between the groups regarding the type of the stent used, all patients received the balloon-expandable, stainless steel NIR stent (Medinol; Boston Scientific).
Methods

Study Design
The study was a multicenter, prospective, randomized trial that was performed at 4 cardiovascular centers in Poland. At each site, Ն400 interventions were performed annually. To participate, each operator was required to perform Ն200 procedures annually with a Ն95% success rate, Ͻ1% mortality rate, and Ͻ5% major in-hospital cardiac event rate in elective procedures.
Study Patients
Symptomatic patients with documented myocardial ischemia and 1-vessel disease were included in the study. The treated vessels had to be Ն2.5 mm in diameter on visual assessment, with Ͼ60% stenosis. Only de novo, noncalcified, and Ͻ15 mm long lesions were included. All patients were required to be acceptable candidates for bypass surgery and to agree to 6-month clinical and angiographic follow-up.
Patients with ostial and bifurcation lesions, recent myocardial infarction (within 7 days of the acute event), allergy to aspirin or ticlopidine, history of bleeding diathesis or coagulopathy, history of stroke or transient ischemic attack within the past 3 months, a positive pregnancy test, or any end-stage disease that influences 6-month survival were excluded from this study. Patients with diabetes mellitus were excluded from the study because of a high incidence of restenosis, of which the mechanism may differ from that in the nondiabetic population.
The ethics committee at each center approved the protocol, and all patients gave written informed consent.
Randomization and Revascularization Strategies.
Eligible patients were randomly assigned to 1 of the treatment modalities. The local drug delivery group received 2500 U heparin through the arterial sheath and 10 mg enoxaparin to the treated site during predilation with the Transport catheter. The catheter has a monorail design with a dual-layer balloon near the distal tip. There is a separate lumen that is used for inflation of the balloon, and a second lumen is used for drug infusion. This allowed uncoupling of the balloon support and drug delivery pressures. The outer balloon has microporous holes located circumferentially along the 10-mmlong mid-section of the balloon for controlled local drug delivery. Radiopaque markers allow for precise placement of the catheter balloon segment.
Lesions were predilated with a balloon-to-artery ratio of 0.9 to 1.0:1.0, and the balloon was inflated at 6 to 8 atm for 30 seconds. The pressure was then lowered to a support pressure of 3 atm, and 10 mg enoxaparin was administered in 1 mL of saline solution at a delivery pressure of 30 to 45 psi (2 to 3 atm) during a 60-to 120-second period.
Patients randomized to stenting with full systemic heparinization (systemic heparinization group) received 10 000 U heparin through the arterial sheath to obtain a target activated clotting time (ACT) of 300 seconds. The baseline ACT was obtained in all patients and was monitored throughout the procedure with the Hemochron 400. The NIR stents (16 mm long, 9-cell design) were deployed with a 1.1:1 balloon-to-artery ratio with noncompliant balloons. Biplane angiograms were performed in all patients using orthogonal projections after the intracoronary administration of 100 to 200 g nitroglycerin. The procedure was deemed successful if there was no residual stenosis by visual estimation, TIMI 3 flow was present, and there were no major cardiac complications (death, myocardial infarction, emergency CABG). Sheaths were removed at an ACT of Ͻ160 seconds. All patients had blood drawn for creatine kinase level determination 6 and 12 hours after the procedure. Values of Ͼ2 times baseline were considered abnormal.
Every patient received 150 mg aspirin QD and 250 mg ticlopidine BID for at least 48 hours before the procedure. The ticlopidine was continued for 4 weeks, and aspirin was continued indefinitely. Complete blood cell counts were determined at baseline and at 2, 4, and 6 weeks. Additional treatment consisted of a calcium channel antagonist or ␤-blockers and nitrates administered at the discretion of the patient's physician.
Clinical and Procedural Data Collection
An independent clinical data collection center was established at the Upper Silesian Cardiology Center in Katowice, Poland. Basic demographic data, risk factors, past medical history, and clinical presentation information were obtained for all patients included in the trial. Any cardiac or noncardiac events were recorded during the 6-month follow-up. Investigators who collected clinical data were blinded to the patient's procedural characteristics. Final data analysis, including procedural data, was performed by the investigator (M.M.R.) not directly involved in the study at the University of Texas Health Science Center at San Antonio.
Angiographic Analysis
The independent core laboratory at University of Texas Health Science Center at San Antonio processed angiographic data. Quantitative coronary angiography was performed off-line, without knowledge of the patient's clinical or procedural characteristics. The Transport drug delivery catheter is indistinguishable from a PTCA catheter in angiographic images. We used a previously validated, 37 interactive automatic edge detection algorithm computer program (Artrek Quantin 2000I; QCS Inc, ImageComm Systems, Inc). Frames that display the most severe lumen narrowing without foreshortening of the selected coronary segment in at least 2 orthogonal projections were selected. The distal end of the guiding catheter was used for calibration in each analyzed projection. Follow-up angiograms were performed with matching views and after the administration of intracoronary nitroglycerin. The same reference segment was selected after intervention and at follow-up. Minimal lumen diameter, lesion length, proximal and distal reference diameters, and luminal diameter stenosis of dilated segments were measured from the coronary angiograms obtained before and just after the procedure, as well as at repeat coronary angiograms 6 months later. Acute and net gain, late loss, and loss index were calculated according to previously described definitions. 38 A Ͼ50%-diameter stenosis was used as a binary definition of restenosis.
Study End Points and Statistical Analysis
The primary end point of the study was late luminal loss at 6 months, not the binary restenosis rate. The sample size (45 patients in each arm) was calculated on the basis of angiographic data from other studies. 39, 40 The study was powered to detect statistically significant differences in the late luminal loss (␣ϭ0.05; difference of mean values to be detected, 0.3 mm; expected SD within groups, Ϯ0.5 mm; power of the test, 80%). The unpaired t test was used for comparison between the 2 groups. 41 Major adverse cardiac events (death, myocardial infarction, emergency CABG, or repeat balloon angioplasty) that targeted lesion revascularization and angiographic restenosis during 6 months were selected as the secondary end points.
All data were expressed as meanϮSD values. Continuous variables were compared using the 2-tailed, Student's t test. Nonparametric values were compared using a 2 test. The right-tailed Fisher's exact test was used to analyze the angiographic restenosis. A value of PϽ0.05 was considered statistically significant.
Results
Between February 1996 and April 1998, 100 patients were prospectively randomized to either receive local drug delivery of low-molecular-weight heparin or full systemic heparinization before stent implantation. All patients received NIR stents. Clinical follow-up was completed for all patients, and 6-month angiographic follow-up was obtained for all except 1 patient. There were no significant differences between the treatment groups in their baseline clinical and angiographic characteristics (Tables 1 and 2 ). The local drug delivery did not prolong the stenting procedure compared with systemic heparinization (Table 3) . Technical data concerning the local drug delivery by means of the Transport catheter are shown in Table 4 . Significant but nonocclusive dissection after predilatation occurred in 4 patients in the local drug delivery group and in 3 patients in the systemic heparinization group (PϭNS); each case was treated with additional stent placement.
ACTs were comparable in the 2 groups at baseline but significantly lower in the local drug delivery group at the end of the procedure (146.9Ϯ39.8 versus 381.9Ϯ182.2 seconds; PϽ0.001), which facilitated earlier removal of the vascular sheaths (Table 3 ). There were no vascular complications in the local drug delivery group: 1 patient in the systemic heparinization group developed hematoma that did not require transfusion. No deaths occurred and no emergent CABGs were performed in either group. One patient in the systemic heparinization group, in whom ticlopidine was discontinued because of an allergic reaction, experienced subacute stent closure and myocardial infarction. This patient was successfully treated with emergency PTCA. Sixty-seven percent of all target lesion revascularizations occurred before the scheduled angiographic follow-up; the remainder of target lesion revascularizations occurred at the time of control angiography, and none occurred afterward. When the local drug delivery group was compared with the systemic heparinization group, there was a statistically significant reduction (8% versus 22%, PϽ0.05) in target lesion revascularization rates at 6 months (Table 5 ). Quantitative coronary angiography revealed no differences at baseline between the 2 groups, and acute results of stenting were comparable. However, at 6-month follow-up, the late luminal loss and loss index were significantly reduced in the local drug delivery group (PϽ0.001) ( Table 6 ), which resulted in a larger late minimal luminal diameter in this group (Figure 1) . Angiographic restenosis after stenting was also significantly reduced to 10% in the local drug delivery group versus 24% in the systemic heparinization group (Pϭ0.049) ( Table 6 ). The total number of major cardiac events (in-hospital and during 6-month follow-up) was significantly diminished in the local drug delivery group (Table 5) . 
Discussion
This current prospective, randomized study demonstrates for the first time that the local delivery of enoxaparin during predilation and before coronary stent implantation reduces late lumen loss and restenosis compared with a conventional stent implantation strategy and systemic heparinization. The study involved Ͻ3.0-mm vessels treated with the first generation of the NIR stent. The late luminal loss and restenosis rates in the control arm correspond well with the findings from other studies, in which Ͻ3.00-mm vessel stenting was performed with the early-generation stents. 42, 43 On the other hand, observed luminal loss and the restenosis rate in the local drug delivery group compare favorably to the results of small vessel stenting. 42, 43 The incidence of subacute closure in this vessel category ranges from 2.5% to 3.6% with full systemic heparinization. 42, 43 In the local drug delivery group, there were no subacute closure events, despite the lack of systemic heparinization. This may suggest a local, persistent antithrombotic effect of enoxaparin.
Our data are in contrast to those of 2 recent studies that examined the impact of the local delivery of a pharmacological agent during coronary stent procedures on long-term outcomes. Neither the Heparin Infusion Prior to Stenting (HIPS) trial, 24 in which unfractionated heparin was delivered after predilation but before stent implantation, nor the ITALICS trial, 25 in which antisense to the proto-oncogene c-myc was delivered after stent implantation, demonstrated an impact on late lumen loss and restenosis.
The effectiveness of local drug therapy may depend on many factors, such as choice of pharmacological agent, methods of drug delivery, and timing with regard to stent deployment. Several studies showed efficacy of local drug delivery. 36,44 -46 Longer infusion and higher drug concentration resulted in greater intramural drug deposition. Moreover, autoradiography demonstrated homogeneous distribution of heparin throughout the intima, media, and adventitia with localization in the nuclei, cytoplasm, and extracellular space. Wash-out studies showed biexponential disappearance of intramurally deposited drug: the rapid release of heparin during the first 60 minutes and the persistence of a small amount of drug for Ն7 days. 44 Our strategy involved the delivery of enoxaparin during predilation to improve intramural penetration of the drug. To prolong retention of the compound, we deployed the stents at the treated vascular segment to seal drug-containing microdissections caused by the balloon injury. This is an important consideration, because studies in animals in which a rabbit model was used for Cumulative distribution of minimal luminal diameter before stenting, immediately after stenting, and at 6 months of angiographic follow-up. Solid lines represent patients randomized to systemic heparinization (SH); dotted lines represent patients randomized to local drug delivery (LDD) and reduced systemic heparinizaiton. MLD indicates minimal luminal diameter; Acute gain, minimal luminal diameter immediately after the procedure minus the diameter before the procedure; Late loss, minimal luminal diameter immediately after the procedure minus the diameter at follow-up; Net gain, minimal luminal diameter at follow-up minus the minimal luminal diameter before the procedure; Loss index, late loss divided by the immediate gain; LDD, local drug delivery; and SH, systemic heparinization.
the intramural delivery of enoxaparin with the Transport catheter without subsequent stenting revealed poor retention of the agent. 33 To avoid significant injury of the treated vascular segment during drug administration, we delivered small volumes of concentrated enoxaparin at low delivery pressures. 35, 36 The design of the Transport catheter allowed for uncoupling of balloon inflation and drug delivery pressures, making drug delivery safe and possible during the predilation.
In the baboon angioplasty model, low molecular weight heparin blocked serum-induced but not platelet-derived growth factor induced smooth muscle cell proliferation and migration, suggesting heparin-sensitive and -insensitive pathways. 47 If the assumption that human smooth muscle cells are less sensitive to growth inhibition by heparin is true, one could consider the possibility that in-stent restenosis may be reduced through the local prevention of early prothrombotic events. The strategy of local delivery of enoxaparin, a potent factor Xa and thrombin inhibitor, 29, 30 during predilation was specifically designed to modulate the magnitude of thrombinand thrombus-mediated stimuli for neointimal proliferation. The purpose of enoxaparin delivery during predilation was to have an antithrombotic agent in place at the time of the initial balloon deflation, when the injured vessel wall is first exposed to circulating prothrombotic elements. This strategy was applied to de novo lesions, which contain tissue factor (factor VIIa) and other procoagulant molecules. 48, 49 Due to its low molecular weight, enoxaparin has the additional advantage of efficient diffusion capability, thus enabling efficient local delivery. However, previous trials in humans with systemic administration of enoxaparin to inhibit restenosis were unsuccessful, possibly due to an insufficient local concentration of low molecular weight heparin at the target lesion. 34 We hypothesized that the local delivery of enoxaparin during predilation and subsequent stenting at the delivery site would result in sufficient concentration and retention to reduce the late luminal loss.
Quantitative analysis of coronary angiography demonstrated that stenting was performed equally effectively in both groups, yielding comparable minimal luminal diameters, known to be strong predictors of restenosis. 50 Therefore, it appears that the observed results can be attributed only to the local delivery of enoxaparin. Normal ACTs at the end of the procedures allowed for immediate sheath removal and faster patient ambulation.
Our study demonstrates, for the first time, a significant decrease in late lumen loss and angiographic restenosis as a result of local delivery of enoxaparin. However, we must stress that our findings are preliminary and require confirmation by a larger trial. The precise antirestenosis mechanism of enoxaparin, although not fully elucidated, is likely the combination of a reduction in thrombotic events, downregulation of thrombotic growth factor generation, and perhaps a direct inhibitory effect on smooth muscle cell proliferation. These data suggest that local drug delivery may constitute a viable therapeutic option to prevent restenosis after coronary stent implantation. Thus, there is a need for a large, randomized trial and the further development of active antiproliferative agents, as well as improved drug delivery devices.
